GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Beneish M-Score
中文

Acura Pharmaceuticals (Acura Pharmaceuticals) Beneish M-Score : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Acura Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Acura Pharmaceuticals was 0.00. The lowest was 0.00. And the median was 0.00.


Acura Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Acura Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Beneish M-Score Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.09 14.26 0.60 -2.67 -

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.67 7.59 -2.09 -5.90 -

Competitive Comparison of Acura Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acura Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Beneish M-Score falls into.



Acura Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Acura Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5756+0.528 * 1+0.404 * 1.3826+0.892 * 0.4378+0.115 * 1.2042
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1237+4.679 * -0.781395-0.327 * 0.1805
=-6.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec21) TTM:Last Year (Dec20) TTM:
Total Receivables was $0.16 Mil.
Revenue was 0.036 + 0.27 + 0.613 + 0.644 = $1.56 Mil.
Gross Profit was 0.036 + 0.27 + 0.613 + 0.644 = $1.56 Mil.
Total Current Assets was $0.37 Mil.
Total Assets was $0.86 Mil.
Property, Plant and Equipment(Net PPE) was $0.44 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.09 Mil.
Selling, General, & Admin. Expense(SGA) was $1.25 Mil.
Total Current Liabilities was $0.52 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.
Net Income was 0.029 + -0.262 + -0.387 + -0.259 = $-0.88 Mil.
Non Operating Income was 0.266 + 0.269 + 0 + 0 = $0.54 Mil.
Cash Flow from Operations was -0.426 + 0.191 + -0.194 + -0.313 = $-0.74 Mil.
Total Receivables was $0.63 Mil.
Revenue was 0.718 + 0.41 + 1.351 + 1.091 = $3.57 Mil.
Gross Profit was 0.718 + 0.41 + 1.351 + 1.091 = $3.57 Mil.
Total Current Assets was $1.18 Mil.
Total Assets was $1.74 Mil.
Property, Plant and Equipment(Net PPE) was $0.48 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.13 Mil.
Selling, General, & Admin. Expense(SGA) was $2.55 Mil.
Total Current Liabilities was $7.52 Mil.
Long-Term Debt & Capital Lease Obligation was $0.11 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.158 / 1.563) / (0.627 / 3.57)
=0.101088 / 0.17563
=0.5756

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.57 / 3.57) / (1.563 / 1.563)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.372 + 0.438) / 0.86) / (1 - (1.179 + 0.484) / 1.736)
=0.05814 / 0.042051
=1.3826

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.563 / 3.57
=0.4378

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.125 / (0.125 + 0.484)) / (0.09 / (0.09 + 0.438))
=0.205255 / 0.170455
=1.2042

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1.253 / 1.563) / (2.547 / 3.57)
=0.801663 / 0.713445
=1.1237

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.167 + 0.515) / 0.86) / ((0.105 + 7.522) / 1.736)
=0.793023 / 4.393433
=0.1805

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.879 - 0.535 - -0.742) / 0.86
=-0.781395

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Acura Pharmaceuticals has a M-score of -6.60 suggests that the company is unlikely to be a manipulator.


Acura Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.
Executives
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly director C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross director 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh officer: VP, Corporate Development
Immanuel Thangaraj director 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser officer: VP, Treasurer & Controller C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones officer: President & CEO C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko officer: VP Pharmaceutical Sciences APT C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens officer: Senior VP & CFO C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc 10 percent owner 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte 10 percent owner 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc 10 percent owner 680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

Acura Pharmaceuticals (Acura Pharmaceuticals) Headlines

From GuruFocus

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx� LTX-03

By GuruFocusNews GuruFocusNews 03-01-2022

Acura Pharmaceuticals Licenses LIMITx™ LTX-03

By Marketwired Marketwired 07-03-2019

Acura Pharmaceuticals Announces Conversion of Debt

By Marketwired Marketwired 06-14-2021

What to Watch for: November 3-7

By TipRanks TipRanks 11-04-2014